Autolus Therapeutics (AUTL) Cash & Equivalents (2017 - 2025)

Autolus Therapeutics (AUTL) has 9 years of Cash & Equivalents data on file, last reported at $104.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 54.2% year-over-year to $104.1 million; the trailing twelve-month figure through Dec 2025 stood at $104.1 million (down 54.2% YoY), and the FY2025 full-year result was $104.1 million, down 54.2% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $104.1 million, up from $86.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $758.5 million in Q1 2024 and bottomed at $86.1 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $239.3 million (2021), against an average of $293.7 million.
• The widest annual swing landed in 2024, when Cash & Equivalents soared 156.25%; it then slumped 87.37% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $310.3 million in 2021, then increased by 23.23% to $382.4 million in 2022, then sank by 37.36% to $239.6 million in 2023, then dropped by 5.09% to $227.4 million in 2024, then slumped by 54.2% to $104.1 million in 2025.
• The last three Cash & Equivalents figures came in at $104.1 million (Q4 2025), $86.1 million (Q3 2025), and $123.8 million (Q2 2025), per Business Quant data.

Peer Comparison